Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries, and affiliates or offices in five countries.
Company profile
Ticker
NVO, NONOF
Exchange
Website
CEO
Lars Fruergaard Joergensen
Employees
Location
Fiscal year end
Industry (SIC)
SEC CIK
NVO stock data
Latest filings (excl ownership)
6-K
Current report (foreign)
20 Mar 23
6-K
Current report (foreign)
13 Mar 23
6-K
Current report (foreign)
7 Mar 23
6-K
Current report (foreign)
6 Mar 23
6-K
Current report (foreign)
27 Feb 23
6-K
Current report (foreign)
22 Feb 23
6-K
Current report (foreign)
22 Feb 23
6-K
Current report (foreign)
14 Feb 23
6-K
Current report (foreign)
14 Feb 23
6-K
Current report (foreign)
8 Feb 23
Latest ownership filings
SC 13G/A
BlackRock Inc.
23 Feb 23
11-K
Annual report of employee stock purchases
28 Jun 22
11-K
Annual report of employee stock purchases
28 Jun 22
SC 13G/A
BlackRock Inc.
1 Feb 22
11-K
Annual report of employee stock purchases
23 Jun 21
11-K
Annual report of employee stock purchases
23 Jun 21
SC 13G/A
BlackRock Inc.
29 Jan 21
11-K
Annual report of employee stock purchases
25 Jun 20
11-K
Annual report of employee stock purchases
25 Jun 20
SC 13G/A
Beneficial ownership report (amended)
5 Feb 20
Financial summary
| Quarter (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
Institutional ownership, Q4 2022
8.2% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 1022 |
| Opened positions | 204 |
| Closed positions | 72 |
| Increased positions | 285 |
| Reduced positions | 345 |
| 13F shares | Current |
|---|---|
| Total value | 19.33 tn |
| Total shares | 143.00 mm |
| Total puts | 589.60 k |
| Total calls | 1.20 mm |
| Total put/call ratio | 0.5 |
| Largest owners | Shares | Value |
|---|---|---|
| Renaissance Technologies | 12.60 mm | $1.70 tn |
| Jennison Associates | 11.45 mm | $1.55 tn |
| Fisher Asset Management | 9.03 mm | $1.22 tn |
| BAC Bank Of America | 6.76 mm | $915.34 bn |
| Capital International Investors | 6.22 mm | $841.51 bn |
| MS Morgan Stanley | 5.21 mm | $705.45 bn |
| Fayez Sarofim & Co | 5.12 mm | $692.45 bn |
| Loomis Sayles & Co L P | 4.98 mm | $671.46 bn |
| BLK Blackrock | 4.62 mm | $625.83 bn |
| Folketrygdfondet | 4.28 mm | $579.91 bn |
News
Looking Into Novo Nordisk's Recent Short Interest
21 Mar 23
If You Invested $100 In This Stock 5 Years Ago, You Would Have $300 Today
17 Mar 23
Three Is Company - Sanofi Follows Lilly, Novo Nordisk, Slashes Insulin Product Price By 78%
17 Mar 23
Novo Nordisk Suspended From UK Trade Association For Practice Breaches
16 Mar 23
Novo Nordisk Has Been Suspended As A Member Of The Association Of The British Pharmaceutical Industry For Two Years Due To Serious Breaches Of The Abpi Code Of Practice
16 Mar 23
Press releases
Novo Nordisk to lower U.S. prices of several pre-filled insulin pens and vials up to 75% for people living with diabetes in January 2024
14 Mar 23
BRTX's ThermoStem®: A New Weapon In The Fight Against Metabolic Syndrome
9 Mar 23
With COVID-19 Having Placed A Sharp Focus On Syringes, This Innovator Looks Back At A Year Of Successes Since Their 2022 IPO
15 Feb 23
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
10 Feb 23
2022 Was A Year Of Growth, Funding, And Positive Results For BioRestorative Therapies
26 Jan 23